Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia

Sponsor

Dongzhimen Hospital, Beijing (Other)

Overall Status

Completed

CT.gov ID

NCT02453932

Collaborator

(none)

543

Enrollment

Location

Arms

Duration (Months)

12.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This ongoing study aimed to evaluate the efficacy and safety of Tianzhi granule in mild to moderate vascular dementia in a more reasonable design.

Condition or Disease	Intervention/Treatment	Phase
Vascular Dementia	Drug: Tianzhi granule and placebo identified to donepezil Drug: Donepezil and placebo identified to Tianzhi granule Drug: Placebo	Phase 3

Detailed Description

This study is a 24-weeks, multicenter, randomized, double-blind, double- placebo, parallel controlled phase III trial being carried out in 23 centers around China. The study population includes mild to moderate VaD patients (planned a total of 630) aged 45-85 in both gender. Participants will be randomly allocated to TZK (15g/d) and placebo identified to donepezil, donepezil (5mg/d) and placebo identified to TZK, or placebo identified to TZK and placebo identified to donepezil for a 24-weeks double-blind treatment period . The primary outcome measure is change from baseline in the Vascular Dementia Assessment Scale-Cognitive Subscale and Clinician's Interview-Based Impression of Change-Plus carer Interview. The secondary outcomes are changes from baseline in the Mini-Mental State Examination, Activity of Daily Living Scale, Clock Drawing Test, Trail Making Test and Neuropsychiatric Inventory. Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.

Study Design

Study Type:

Interventional

Actual Enrollment :

543 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia

Study Start Date :

Oct 1, 2013

Actual Primary Completion Date :

May 1, 2017

Actual Study Completion Date :

May 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Tianzhi granule Tianzhi granule and placebo identified to donepezil	Drug: Tianzhi granule and placebo identified to donepezil 1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
Active Comparator: Donepezil Donepezil and placebo identified to Tianzhi granule	Drug: Donepezil and placebo identified to Tianzhi granule donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
Placebo Comparator: Placebo Placebo identified toTianzhi granule and placebo identified to donepezil	Drug: Placebo placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks

Arm

Intervention/Treatment

Experimental: Tianzhi granule

Tianzhi granule and placebo identified to donepezil

Drug: Tianzhi granule and placebo identified to donepezil

1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks

Active Comparator: Donepezil

Donepezil and placebo identified to Tianzhi granule

Drug: Donepezil and placebo identified to Tianzhi granule

donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks

Placebo Comparator: Placebo

Placebo identified toTianzhi granule and placebo identified to donepezil

Drug: Placebo

placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks

Outcome Measures

Primary Outcome Measures

Changes of Vascular Dementia Assessment Scale-Cognitive Subscale(VADAS-cog) from baseline after 24 weeks' intervention [week 0, 4, 12, 24]
Cognition : VaDAS-cog is a revision of the ADAS-cog to be a better measure in vascular conditions. The original ADAS-cog developed by Rosen et al., measures cognitive performance by combining ratings of 11 items. The cognitive domains mainly addressed by ADAS-cog are memory (short term), language, ability to orientate (reflects memory), construction/planning of simple designs and performance. In addition to ADAS-cog, the VaDAS-cog comprises additional frontal lobe tests reflecting attention, working memory, executive function, and verbal fluency.The VADAS-cog will conducted at baseline, 4weeks, 12weeks, 24weeks
Changes of Clinician's Interview-Based Impression of Change-Plus carer Interview(CIBIC-plus) from baseline after 24 weeks' intervention [week 0, 4, 12, 24]
Overall clinical response: CIBIC-plus is a 7-point scale which provides an index of clinically important change for dementia patients. It is a global measure of detectable change in concentration, orientation, memory, language, behavior, initiative and activities of daily living, usually requiring separate interviews with patients and caregivers,the CIBIC-plus will be conducted at baseline, 4weeks, 12weeks, 24weeks

Secondary Outcome Measures

Changes of Mini-Mental State Examination(MMSE) from baseline after 24 weeks' treatment [week 0, 4, 12, 24]
Global cognition will be assessed by the MMSE,which will be conducted at baseline, 4weeks, 12weeks, 24weeks.
Changes of Activity of Daily Living Scale(ADL) from baseline after 24 week's intervention [week 0, 4, 12, 24]
Function:The ADL mainly used to measure the basic activities of daily living (or self-care) and the instrumental activities of daily living. The ADL scale can be divided to Physical Self-Maintenance Scale (PSMS) and the instrumental activities of daily living (IADL). The PSMS relate to physical activities, such as toileting, mobility, dressing and bathing , and the IADL contains 8 items ,such as shopping, cooking, doing laundry, handling finances, using telephone, mode of transportation, responsibility for own medication and housekeeping.The ADL wil be conducted baseline, 4weeks, 12weeks, 24weeks
Changes of Clock Drawing Test(CDT) from baseline after 24 week's intervention [week 0, 4, 12, 24]
Executive function and Visuospatial function : the CDT scale will be conducted at baseline, 4weeks, 12weeks, 24weeks.
Changes of Trail Making Test (TMT) from baseline after 24 week's intervention [week 0, 4, 12, 24]
Executive function: The TMT scale will be conducted at baseline, 4weeks, 12weeks, 24weeks.
Changes of Neuropsychiatric Inventory(NPI) from baseline after 24 weeks' intervention [week 0, 4, 12, 24]
Changes in psychological symptom: NPI is used throughout the study to assess changes in psychological symptom,the NPI will be conducted at baseline, 4 weeks, 12 weeks, 24 weeks.

Eligibility Criteria

Criteria

Ages Eligible for Study:

45 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Inpatients and outpatients meeting the diagnostic criteria probable VaD established according to the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) （DSM-Ⅳ） and the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)were eligible to participate,
diagnosis of mild to moderate vascular dementia;
Chinese-speaking patients aged ≥45 and≤85 years old in both gender;
weighing between 45 and 90kg;
fully conscious;
MMSE score of≤26 and ≥14;
HIS score of ≥7;
adequate vision and hearing ability to complete all study tests;
with a stable caregiver.

Exclusion Criteria:

Patients will be excluded from the enrollment if they meet any of the followings:

a medical history of other dementia types, like Alzheimer's disease, Parkinson's disease dementia, Huntington disease, Normal pressure hydrocephalus, et al;
major depression (HAMD for 17 items>17) or psychotic disorder;
acute stage of cerebral hemorrhage or subarachnoid hemorrhage;
hypothyroidism;
drug or alcohol abuse;
epilepsy history; myasthenia gravis history;
severe cardiovascular disease(severe arrhythmia with heart rate≥100 or≤60 times per min, left bundle branch block, myocardial infarction within 3 months, systolic pressure≥180mmHg or ≤90mmHg);
severe liver or kidney dysfunction (alanine aminotransferase>60 IU/L, aspartate transaminase>60 IU/L or serum creatinine >266μmol/L);
severe asthma or chronic obstructive pulmonary disease;
gastrointestinal tract obstruction or severe peptic ulcer; glaucoma;
administration of cholinesterase inhibitors, memantine or nimodipine in the last month;
use of sympathomimetic agent, antihistamine drug, antianxiety drugs or tranquilizer within 48h before assessment;
use of antipsychotic drugs within 72h before assessment;
participation in other clinical trials; allergic history to any type of medication used in this study.